SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 10, 2003
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware | 000-23265 | 94-3267443 | ||
(State or other jurisdiction of incorporation) | (Commission file Number) | (IRS Employer ID Number) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina | 27615 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
Item 5. Other Events and Regulation FD Disclosure
Salix Pharmaceuticals, Ltd. issued a press release on April 10, 2003, announcing that it had received an unsolicited offer from Axcan Pharma Inc. to acquire all of its outstanding common stock for $8.75 per share. A copy of this press release is attached as an exhibit.
Item 7. Financial Statements and Exhibits
(c) Exhibits
| 99.1 Press | Release dated April 10, 2003 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||||||||
Date: April 10, 2003 | By: | /s/ ADAM C. DERBYSHIRE | ||||||
Adam C. Derbyshire Vice President and Chief Financial Officer | ||||||||
